Receiving oncology study submissions that propose a too-wide range of types and formats of real world data (RWD) — along with a lack of basic elements of study design — has prompted the creation of the FDA’s new Oncology Quality, Characterization, and Assessment of Real-world Data (QCARD) Initiative.
Source: Drug Industry Daily